Treats mild to moderate atopic dermatitis. ANDA 209556, held by The J Molner. Hydrocortisone Butyrate.
As of Nov 16, 2026, ANDA 209556 (Hydrocortisone Butyrate), held by The J Molner, was first approved by FDA on Nov 21, 2017, with 1 approved supplement and 0 published complete response letters.
Hydrocortisone Butyrate Lotion is indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 21, 2017 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydrocortisone Butyrate0.1% · lotion;topical | Hydrocortisone Butyrate | Rx |
| Apr 30, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 21, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters